The global viscosupplementation market is experiencing robust growth and is expected to reach a valuation of US$ 7.81 billion by 2030, driven by the increasing prevalence of osteoarthritis (OA) and the rising demand for non-surgical, minimally invasive treatment options. Viscosupplementation, particularly through hyaluronic acid (HA) injections, has emerged as a cornerstone treatment for managing osteoarthritis, offering significant relief to patients with fewer side effects compared to traditional methods like corticosteroid injections.

 

Request a free sample copy of the report: https://www.renub.com/viscosupplementation-market-p.php

 

 

Viscosupplementation: A Non-Surgical Alternative with Growing Popularity

 

Viscosupplementation involves the injection of hyaluronic acid derivatives into the affected joints, which helps to restore lubrication, reduce inflammation, and promote healing. The procedure is especially effective for knee osteoarthritis, a condition where cartilage degeneration leads to pain, stiffness, and reduced mobility. As an outpatient procedure, viscosupplementation offers patients a less invasive, cost-effective alternative to surgery while significantly reducing reliance on opioid analgesics and non-steroidal anti-inflammatory drugs (NSAIDs).

 

The growing prevalence of age-related joint diseases, particularly osteoarthritis, is a primary factor driving market growth. With the global population aging rapidly, especially in regions like North America and Europe, the need for effective joint pain treatments is escalating. According to the United Nations, the global elderly population is expected to double to 1.5 billion by 2050, further increasing the demand for OA treatments. In countries like copyright, the aging population is expected to constitute about 25% of the total population by 2043, which will fuel the adoption of viscosupplementation therapies.

 

Market Growth and Key Drivers

 

The viscosupplementation market is anticipated to grow at a compound annual growth rate (CAGR) of 8.97% from 2024 to 2030. Key growth drivers include:

 

1. Rising Prevalence of Osteoarthritis and Osteoporosis: OA remains the most common form of arthritis, particularly affecting the knee and hip joints. The aging demographic and lifestyle factors contribute to the rising incidence of OA, making viscosupplementation an increasingly attractive option for pain management.
2. Minimal Invasiveness and Convenience: The single-injection viscosupplementation option is particularly gaining traction. Unlike the multi-injection alternatives, the single-dose treatments offer convenience, reduced treatment time, and enhanced patient satisfaction. This ease of use is expected to significantly drive market growth.

 

1. Non-Surgical Alternatives: As healthcare trends shift towards non-invasive procedures, viscosupplementation offers a favorable alternative to surgical interventions like knee replacements. Patients seeking faster recovery times and fewer complications are more likely to choose this non-surgical option.

 

1. Government Support and Health Insurance Coverage: Favorable reimbursement policies and government support in many countries are making viscosupplementation more accessible to a wider range of patients. Additionally, investments from pharmaceutical companies in developing innovative drugs and treatment methods are further contributing to market expansion.

 

1. Expansion of Ambulatory Surgical Centers (ACS): The rise of specialized clinics and ambulatory surgical centers is helping to make viscosupplementation more accessible to patients. These centers are equipped to handle outpatient procedures efficiently, catering to the growing demand for orthopedic care without the need for lengthy hospital stays.

 

Segment Insights: Single-Injection Treatments Lead the Way

 

The market is segmented by product type, with single-injection viscosupplementation poised for significant growth. This growth is primarily driven by the convenience of the procedure, as it offers an efficient solution for patients seeking immediate relief from joint pain. Companies are also focused on developing single-injection treatments that address the needs of patients with knee osteoarthritis, thereby expanding their market share.

 

By application, the knee osteoarthritis segment remains the dominant force in the market. Knee osteoarthritis is particularly prevalent in the aging population, where the loss of cartilage and reduced hyaluronic acid in the knee joints contribute to pain and dysfunction. The treatment of knee OA with viscosupplementation helps improve joint function and alleviate pain, making it a highly sought-after solution in the orthopedic sector.

 

Regional Outlook: North America and China Leading the Charge

 

The viscosupplementation market is poised to grow substantially across all regions, with North America and China expected to be major contributors. In North America, particularly the United States, the market is expanding due to a large population of OA sufferers seeking non-surgical alternatives to joint replacement. As per the Centers for Disease Control and Prevention (CDC), approximately 34.5 million Americans suffer from osteoarthritis annually, driving the demand for viscosupplementation treatments.

 

China is also expected to emerge as a significant player in the viscosupplementation market, thanks to its aging population, increased healthcare awareness, and the rising incidence of osteoarthritis. Market dynamics in China may fluctuate due to changing healthcare policies and evolving medical practices, but the overall trend indicates a strong growth trajectory.

 

Key Players Driving Innovation in the Market

 

Leading companies in the viscosupplementation market include Anika Therapeutics Inc., Zimmer Biomet, Smith & Nephew PLC, F. Hoffmann-La Roche Ltd., Sanofi, Chugai Pharmaceutical Co., Lifecore Biomedical, and LG Life Sciences Ltd. These companies are investing heavily in research and development to advance viscosupplementation therapies and expand their product portfolios. Collaboration and partnerships within the industry are also helping to push the boundaries of treatment options, with new formulations and injection techniques being developed to cater to a wider array of patients.

 

 

Related Reports:

 

Adhesion Barriers Market:  https://www.renub.com/adhesion-barriers-market-p.php

 

Bariatric Surgery Devices Market:  https://www.renub.com/bariatric-surgery-devices-market-p.php

 

Biopreservation Market:  https://www.renub.com/biopreservation-market-p.php

 

 

About the Company:

Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.

Media Contact:

Company Name: Renub Research

Contact Person: Rajat Gupta, Marketing Manager

Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)

Email: [email protected]